Business Wire

Helfie AI Bolsters Operational and Strategic Growth With Appointment of Two Influential Industry Leaders to Executive Team

31.7.2025 14:00:00 CEST | Business Wire | Press Release

Share

Helfie AI, aglobal mobile health platform, today announced the appointment of two new members of the executive leadership team, Stefan Kulik as Chief Operating Officer and Rania Awad as Chief Strategy Officer.

Helfie AI is building the world’s first human health platform, powered by artificial intelligence, to enable anyone with a smartphone anywhere in the world access to easy, instant and affordable health checks. The additions of Mr. Kulik and Ms. Awad to the leadership team strengthens Helfie AI’s capacity to deliver an AI solution to healthcare that emphasizes data ownership, universal access and freedom of choice, enabling early disease detection and prevention on a global scale.

Helfie AI co-founder and CEO George Tomeski said: “The expansion of our leadership team to include Stefan and Rania is a pivotal moment in Helfie’s growth. As we reach across communities worldwide and deliver on our vision of providing an accurate and cost-effective way for patients to obtain health checks, we will rely on their expertise to realize this mission. I look forward to working with them as we continue to develop our Human Health Network platform to bring it to all 8 billion humans worldwide.”

Kulik has over 15 years of experience serving in executive roles at recognizable companies such as PepsiCo, Johnson & Johnson, and Royal Mail. In each of these leadership roles he developed deep expertise in operational excellence and business development. Kulik also has significant experience in private equity and venture capital environments, with specialized knowledge in predictive analytics and artificial intelligence applications. His unique combination of corporate leadership experience and insights gained from working with elite athletes in performance optimization and behavioural change positions him well to drive Helfie AI's continued growth and strategic objectives.

Awad is an accomplished digital strategist and innovator with extensive experience as a licensed pharmacist and business leader. She brings a proven track record of scaling organizations, spearheading digital transformation initiatives, and developing comprehensive product and go-to-market strategies. Her cross-industry expertise spans healthcare, asset management, retail and information technology sectors, with demonstrated success across the Asia-Pacific region, including Australia, New Zealand, and China. Awad's unique combination of pharmaceutical expertise and strategic business acumen positions her to drive Helfie's strategic vision and market expansion objectives.

​“Helfie AI is revolutionising the healthcare field by providing consumers with a cost-effective and accurate AI-powered platform, so I look forward to applying my organisational expertise to help achieve this vision on a global scale,” said Kulik. “As we expand Helfie AI’s global growth strategy within the UK, broader international markets, and the US, I will work with my colleagues to bring this critical technology to those who need it most.”

“Helfie AI’s technology aims to bring equitable health access globally to bypass complicated healthcare systems and put AI-powered mobile health checks into individual hands,” said Awad. "In the near-term, I will use my expertise in strategic marketing to help Helfie AI achieve its next stage of growth, which includes a consumer launch and expanded partnerships with organizations and governments worldwide. I’m confident that the expanded leadership team will deliver on Helfie AI’s mission to become the most trusted AI health company in the market.”

Helfie AI's advanced AI technologies analyse pictures, videos, sound recordings or face scans to check for indications of potential health conditions. Helfie AI generates instant results and offers the user information and options on what to do next. Importantly, the user owns and controls all of the data provided as part of the checks.

About Helfie AI
Helfie AI was founded in Melbourne, Australia in 2021 and has expanded operations to Europe, North America, Africa and Asia with multiple active B2B partnerships with top tier companies already in place.

Helfie AI tackles two of healthcare’s most fundamental challenges: the lack of participation in preventative healthcare and the under-utilisation of health data. Every facet of healthcare, starting with the quality and longevity of human life, can be dramatically improved if everyone actively participates in preventative health and if health data is actively utilized throughout the healthcare system.

The accessibility made possible by Helfie AI can significantly reduce the $7 trillion spent annually on treating preventable conditions.

Helfie AI provides users with clear next steps, connects them to medical care if/as required, allows interaction around numerous health conditions, from cardiovascular to skin health, and enables sharing AI findings with their own carers and doctors.

More details on the checks Helfie can make are available at www.helfie.ai

View source version on businesswire.com: https://www.businesswire.com/news/home/20250731802386/en/

Contacts

Media Contacts:

Chris Welsh, ICR Healthcare Europe
Alexis Feinberg, ICR Healthcare US
Helfie@ICRHealthcare.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye